Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120

Zhiwei Wu, Donald Van Ryk, Cheryl Davis, William R. Abrams, Irwin Chaiken, John Magnani, Daniel Malamud

    Research output: Contribution to journalArticlepeer-review


    Salivary agglutinin (SAG) is a high molecular mass glycoprotein (340 kDa) that plays important roles in innate immunity. SAG has been found to specifically inhibit HIV-1 infectivity and to bind to virus through the envelope protein gp120. Although SAG binds to gp120 of the virus, the exact nature of this binding has not been characterized. Using surface plasmon resonance technology, we have found that SAG interacts with recombinant envelopes derived from diverse HIV-1 isolates with KD values ranging from 10-7 to 10-10 M, comparable to gp120-sCD4 binding. Furthermore, SAG binding to gp120 is Ca2+ dependent, sCD4 prebound to gp120 failed to abrogate SAG binding, suggesting a distinct mechanism for SAG inhibition of HIV-1 infectivity. Inhibition by monoclonal antibodies specific for carbohydrates also implicates the involvement of carbohydrates in the interaction between SAG and gp120. These results argue that the anti-HIV-1 activity of SAG is due to carbohydrate-mediated binding to gp120. A demonstration that SAG is related to lung scavenger receptor, gp-340, further suggests the roles of SAG in preventing pathogen invasion at the entry portal and raises its potential as an anti-HIV-1 drug candidate.

    Original languageEnglish (US)
    Pages (from-to)201-209
    Number of pages9
    JournalAIDS Research and Human Retroviruses
    Issue number3
    StatePublished - Mar 1 2003

    ASJC Scopus subject areas

    • Immunology
    • Virology
    • Infectious Diseases


    Dive into the research topics of 'Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120'. Together they form a unique fingerprint.

    Cite this